Multifaceted roles of long non-coding RNAs in triple-negative breast cancer: biology and clinical applications

Rajagopal, Taruna; Talluri, Srikanth; Venkatabalasubramanian, Sivaramakrishnan; Dunna, Nageswara Rao

doi:10.1042/bst20200666

Cited by 4 publications

(4 citation statements)

References 166 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanocarriers are being explored as versatile delivery systems to enhance therapeutic agents' specificity and efficacy. [65] Current methods have limitations, and nanotherapeutic-based platforms are being investigated. A bio-scaffold containing lncRNA-targeting biomimetic nanostructures was created to modulate immune responses against colorectal cancer recurrence after surgery.…”

Section: Targeting Lncrnas For Therapeutic Applications; Nanocarriers...mentioning

confidence: 99%

See 1 more Smart Citation

Nanomaterials‐Based Targeting of Long Non‐Coding RNAs in Cancer: A Cutting‐Edge Review of Current Trends

Davodabadi,

Farasati Far,

Sargazi

et al. 2024

ChemMedChem

View full text Add to dashboard Cite

This review article spotlights the burgeoning potential of using nanotherapeutic strategies to target long non‐coding RNAs (lncRNAs) in cancer cells. This updated discourse underlines the prominent role of lncRNAs in instigating cancer, facilitating its progression, and metastasis, validating lncRNAs' potential for being effective diagnostic biomarkers and therapeutic targets. The manuscript offers an in‐depth examination of different strategies presently employed to modulate lncRNA expression and function for therapeutic purposes. Among these strategies, Antisense Oligonucleotides (ASOs), RNA interference (RNAi) technologies, and the innovative CRISPR‐based gene editing tools garner noteworthy mention. A significant section of the review is dedicated to nanocarriers and their crucial role in drug delivery. These nanocarriers' efficiency in targeting lncRNAs in varied types of cancers is elaborated upon, validating the importance of targeted therapy. The manuscript culminates by reaffirming the promising prospects of targeting lncRNAs to enhance the accuracy of cancer diagnosis and improve treatment efficacy. Consequently, new paths are opened to more research and innovation in employing nanotherapeutic approaches against lncRNAs in cancer cells. Thus, this comprehensive manuscript serves as a valuable resource that underscores the vital role of lncRNAs and the various nano‐strategies for targeting them in cancer treatment.

show abstract

Section: Targeting Lncrnas For Therapeutic Applications; Nanocarriers...mentioning

confidence: 99%

“… [23] However, effective delivery remains a challenge. Nanocarriers are being explored as versatile delivery systems to enhance therapeutic agents′ specificity and efficacy [65] . Current methods have limitations, and nanotherapeutic‐based platforms are being investigated.…”

Section: Targeting Lncrnas For Therapeutic Applications; Nanocarriers...mentioning

confidence: 99%

Nanomaterials‐Based Targeting of Long Non‐Coding RNAs in Cancer: A Cutting‐Edge Review of Current Trends

Davodabadi,

Farasati Far,

Sargazi

et al. 2024

ChemMedChem

View full text Add to dashboard Cite

show abstract

“…Long non-coding RNAs (lncRNAs) are a new class of stem cell regulators that play important roles in a wide range of cellular processes [ 15 ]. Studies employing powerful new technologies and bioinformatics tools have identified lncRNAs (with greater than 200 nucleotides in length) that can regulate oncogene expression by binding to chromatin-modifying factors and transcription factors or altering the splicing, stability, or translation of mRNAs [ 16 , 17 , 18 , 19 ]. The expression patterns and functions of lncRNAs are highly cell-type specific.…”

Section: Introductionmentioning

confidence: 99%

A Proof-of-Concept Inhibitor of Endothelial Lipase Suppresses Triple-Negative Breast Cancer Cells by Hijacking the Mitochondrial Function

Yang

Han

Clayton

et al. 2022

Cancers

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) cells reprogram their metabolism to provide metabolic flexibility for tumor cell growth and survival in the tumor microenvironment. While our previous findings indicated that endothelial lipase (EL/LIPG) is a hallmark of TNBC, the precise mechanism through which LIPG instigates TNBC metabolism remains undefined. Here, we report that the expression of LIPG is associated with long non-coding RNA DANCR and positively correlates with gene signatures of mitochondrial metabolism-oxidative phosphorylation (OXPHOS). DANCR binds to LIPG, enabling tumor cells to maintain LIPG protein stability and OXPHOS. As one mechanism of LIPG in the regulation of tumor cell oxidative metabolism, LIPG mediates histone deacetylase 6 (HDAC6) and histone acetylation, which contribute to changes in IL-6 and fatty acid synthesis gene expression. Finally, aided by a relaxed docking approach, we discovered a new LIPG inhibitor, cynaroside, that effectively suppressed the enzyme activity and DANCR in TNBC cells. Treatment with cynaroside inhibited the OXPHOS phenotype of TNBC cells, which severely impaired tumor formation. Taken together, our study provides mechanistic insights into the LIPG modulation of mitochondrial metabolism in TNBC and a proof-of-concept that targeting LIPG is a promising new therapeutic strategy for the treatment of TNBC.

show abstract

“…Recent research has revealed the enormous promise for miRNAs to improve the diagnosis, and management of all major gynecological cancers (cervical, endometrial and ovarian cancers) [1]. This is backed up by research on miRNAs in other cancers such as thyroid, breast and gastric cancer [13][14][15]. Numerous miRNAs are believed to influence multiple biological functions, leading to modulation of the tumor microenvironment, including stemness, growth, proliferation, invasion and metastasis [1].…”

Section: Introductionmentioning

confidence: 99%

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

Fiore

Suleiman

Pentimalli

et al. 2021

IJMS

View full text Add to dashboard Cite

Gynecological cancers pose an important public health issue, with a high incidence among women of all ages. Gynecological cancers such as malignant germ-cell tumors, sex-cord-stromal tumors, uterine sarcomas and carcinosarcomas, gestational trophoblastic neoplasia, vulvar carcinoma and melanoma of the female genital tract, are defined as rare with an annual incidence of <6 per 100,000 women. Rare gynecological cancers (RGCs) are associated with poor prognosis, and given the low incidence of each entity, there is the risk of delayed diagnosis due to clinical inexperience and limited therapeutic options. There has been a growing interest in the field of microRNAs (miRNAs), a class of small non-coding RNAs of ∼22 nucleotides in length, because of their potential to regulate diverse biological processes. miRNAs usually induce mRNA degradation and translational repression by interacting with the 3′ untranslated region (3′-UTR) of target mRNAs, as well as other regions and gene promoters, as well as activating translation or regulating transcription under certain conditions. Recent research has revealed the enormous promise of miRNAs for improving the diagnosis, therapy and prognosis of all major gynecological cancers. However, to date, only a few studies have been performed on RGCs. In this review, we summarize the data currently available regarding RGCs.

show abstract

Multifaceted roles of long non-coding RNAs in triple-negative breast cancer: biology and clinical applications

Cited by 4 publications

References 166 publications

Nanomaterials‐Based Targeting of Long Non‐Coding RNAs in Cancer: A Cutting‐Edge Review of Current Trends

Nanomaterials‐Based Targeting of Long Non‐Coding RNAs in Cancer: A Cutting‐Edge Review of Current Trends

A Proof-of-Concept Inhibitor of Endothelial Lipase Suppresses Triple-Negative Breast Cancer Cells by Hijacking the Mitochondrial Function

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

Contact Info

Product

Resources

About